Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PD-L1 >= 1%, PR negative status confers therapeutic sensitivity to Atezolizumab, Nab-paclitaxel in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
TECENTRIQ (atezolizumab) in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering ≥ 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.